Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Decorin" patented technology

Decorin is a protein that in humans is encoded by the DCN gene. Decorin is a proteoglycan that is on average 90 - 140 kilodaltons (kDa) in molecular weight. It belongs to the small leucine-rich proteoglycan (SLRP) family and consists of a protein core containing leucine repeats with a glycosaminoglycan (GAG) chain consisting of either chondroitin sulfate (CS) or dermatan sulfate (DS).

Pharmaceutical composition for treating degenerative ocular diseases and use thereof

A pharmaceutical composition containing a stem cell secretion, and a pharmaceutically acceptable excipient thereof. The protein in the stem cell secretion comprises one, two or three proteins selected from a group consisting of a pigment epithelium-derived factor (PEDF), a tissue inhibitor of metalloproteinase 1 (TIMP-1), a secreted protein acidic and rich in cysteine (SPARC), an α2-HS glycoprotein (AHSG), a periostin (POSTN), a decorin (DCN), the retinoic acid receptor responder 2 (RARRES2), the glia-derived nexin (GDN), the Sparc / osteonectin, cwcv and kazal like domains proteoglycan 1 (SPOCK1), and the follistatin-like 1 (FSTL1). The pharmaceutical composition is used for treating degenerative ocular diseases including retinal degeneration, retinitis pigmentosa, glaucoma, macular degeneration, etc.
Owner:BUDDHIST TZU CHI GEN HOSPITAL

Homing peptide-directed decorin conjugates for the treatment of epidermolysis bullosa

The present invention relates to homing peptide-directed decorin conjugates for the treatment of epidermolysis bullosa, and corresponding methods of treatment. The use of novel homing peptides enables the targeting of the conjugates in vivo to specifically home to the skin and skin wounds by systemic administration.
Owner:TAMPERE UNIV REGISTERED FOUNDATION

Adhesion molecules for targeted infiltration of therapeutic cells

The present disclosure pertains to a cell that expresses at least one binding protein, such as decorin binding protein A (DbpA), decorin binding protein B (DbpB), or combinations thereof. The cell may include immune cells, such as chimeric antigen receptor T-cells. The present disclosure also pertains to methods of treating or preventing a disease in a subject by administering a cell of the present disclosure to the subject. The present disclosure also pertains to methods of forming the cells of the present disclosure by expressing at least one binding protein in the cell.
Owner:UNIV HOUSTON SYST

Decorin for its use in the treatment of diabetes

PendingUS20260124282A1Metabolism disorderPeptide/protein ingredientsPhysiologyIslet cell transplantation
Decorin or a composition containing decorin for use in the treatment of type 1 diabetes, type 2 diabetes or gestational diabetes is described herein. Decorin or a composition containing decorin is also described for use in the context of transplanting pancreatic islet cells.
Owner:CENT EUROEN DETUD DU DIABETE

MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND THEIR USE

The present invention relates to multifunctional protein molecules comprising decorin and their uses. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody, and methods for their production and uses.
Owner:CATALENT PHARMA SOLUTIONS INC